The FDA Just Changed the Rules on Menopausal Hormone Therapy. Here's What That Means for You.
Written and Medically Reviewed by NP Julia Standefer
If you've been putting off a conversation about hot flashes, night sweats, poor sleep, brain fog, or that "I don't feel like myself anymore" feeling — this is the moment to stop waiting. The federal government just rewrote more than two decades of warnings on menopausal hormone therapy (MHT), and it's opening the door for more women to get real relief. At Sanctuary Health, we've been fielding a surge of questions about what changed and whether hormone therapy is finally safe to consider. Here's the full picture with the research to back it up.
What actually changed
For over 20 years, every estrogen-containing menopausal hormone therapy product has carried a "black box" warning — the FDA's most serious label — citing risks of breast cancer, heart attack, stroke, and dementia. That warning traces back to the 2002 Women's Health Initiative (WHI) study whose results single-handedly left thousands of women without access to treatment for menopausal symptoms [1].
That's now changing. On November 10, 2025, the agency announced it would remove the black box warning from every hormone therapy product containing estrogen [2]. The removal officially went into effect in February 2026 [3].
The updated labeling covers six menopausal hormone therapy products; it clarifies risk language around cardiovascular disease, breast cancer, and dementia that had been part of the boxed warning [3]. The change applies across four categories of therapy: combined estrogen and progesterone, estrogen-alone therapy, progesterone-alone therapy for women using systemic estrogen, and topical vaginal estrogen [3].
FDA Commissioner Dr. Marty Makary framed the shift bluntly, saying tens of millions of women had been denied the long-term benefits of menopausal hormone therapy because of a distortion of risk [3]. For more than two decades, those warnings steeply dropped women’s access and usage of hormone therapy for disruptive menopausal symptoms [3]. As newer research shows, timing of hormone therapy factors more than almost anything else. The labels being rewritten now include age-specific guidance, indicating that women may see long-term health benefits when MHT starts within 10 years of menopause onset [2].
Why this is happening now — the science caught up
The 2002 WHI findings incompletely captured the complexity of risk profiles. Subsequent re-analyses have reframed the risk-benefit picture of hormone therapy based on a woman's age at initiation, time since menopause, route of administration, dose, and choice of progestogen type [6]. For example, a 52-year-old starting a low-dose estrogen transdermal patch two years into menopause has a completely different risk than the 63-year-old average participant who was taking an oral tablet of estrogen in the original WHI trial.
What the emerging research shows
This isn't just about symptom relief anymore (though that matters!). A growing body of research points to real, measurable health benefits when menopausal hormone therapy is started at the right time of life:
Bone health. Estrogen-containing MHT prevents early postmenopausal bone loss, reducing fracture risk in appropriately selected women [6]. A retrospective cohort study went further, finding that hormone therapy use was associated with a 69% reduced risk of low bone density in postmenopausal women [7].
Cardiovascular health. Early initiation of MHT within 10 years of menopause onset consistently shows cardiovascular benefits [8]. That said, we want to be precise here: cardiovascular prevention on its own is not an FDA-approved indication for menopausal hormone therapy [6] — the benefit shows up as a byproduct of appropriately timed treatment for menopausal symptoms, not as a standalone reason to start.
Cognitive health. This is one of the more exciting frontiers. Early research suggests women may reduce their risk of Alzheimer's disease by roughly 35% when hormone therapy is started at the right time [10] — though this is an emerging finding, not a settled one, and it depends heavily on timing and formulation.
Genitourinary health. Hormone therapy remains the first-line treatment for genitourinary syndrome of menopause. Treatment can help reduce the reccurence of urinary tract infections in women [11].
Whole-body and metabolic health. Some researchers now describe hormone therapy as having broader protective effects across systems — potentially slowing the progression of atherosclerosis or reducing postmenopausal bone loss [9]. These early findings are part of a larger shift toward viewing menopausal hormone treatment as whole-body preventive medicine, not just symptom management.
What patients are telling us
We want to be careful here, because this is exactly where a lot of wellness marketing goes wrong: anecdotes are not proof, and we're not going to tell you menopausal hormone therapy cures everything. But patient-reported experience matters, and it's worth hearing others’ stories. This is to hear what is possible and ask your Dr. what improvements could await you. Women coming in reporting years of unexplained fatigue, disrupted sleep, and being told their labs are "normal." Some women describe getting started on the right formulation as life-changing. We cannot give a guarantee of results, but by carefully gathering your cycle history, sleep, mood, cardiovascular risk factors we can build a plan towards the best outcomes.
How to advocate for yourself in this new landscape
The label change doesn't mean menopausal hormone therapy is right for everyone, or that every provider is up to speed yet. Plenty of clinicians were trained under the old warning and haven't updated their approach. Here's how to walk into that conversation prepared:
Know your optimal window. If you are within 10 years of menopause onset, or under 60 years of age, you can ask if you are a candidate to take MHT safely. This single factor drives a large part of the risk-benefit calculation. Some women outside of this window may still qualify, based on a risk vs. benefit discussion.
Ask about route that works for your lifestyle AND your symptoms. Transdermal patches, gels, and vaginal preparations carry lower risk profiles than oral pills. If a provider only offers one option, ask why! Speak up for yourself if you feel one method might work better for you than others.
Inquire even if your labs are “normal.” If you are told you do not need menopausal hormone therapy because your have normal hormone levels, ask more questions. This is a red flag the provider may not be up to date in hormone research.
Provide your personal risk factors. A history of blood clots, heart disease, stroke, hormone-sensitive cancer, liver disease, nicotine use, all change the calculation.
Don't accept "it's just aging." Hot flashes, night sweats, brain fog, and mood changes are possibly treatable symptoms — not something you have to white-knuckle through for a decade.
How Sanctuary Health can help
This labeling change is a genuine turning point, but it also means the conversation just got more nuanced. We stay current on this research so you don't have to sort through it alone, and we build a menopausal hormone therapy plan (if it's right for you) around your history, your labs, and your goals — not a one-size-fits-all prescription. If you're navigating perimenopause or menopause symptoms and want a provider who will dig into your case with you, reach out to Sanctuary Health and let's talk through your options!
This article is for educational purposes and isn't a substitute for individualized medical advice. Hormone therapy carries risks that vary by personal and family history, and any decision should be made with a qualified provider who knows your full health picture.
References - accurate as of September 2026
Writing Group for the Women's Health Initiative Investigators. Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women: Principal Results From the Women's Health Initiative Randomized Controlled Trial. JAMA. 2002;288(3):321–333. doi:10.1001/jama.288.3.321 https://jamanetwork.com/journals/jama/fullarticle/195120
Harvard Health Publishing. "FDA removes menopause hormone therapy black box warnings." Harvard Medical School, Nov. 13, 2025. https://www.health.harvard.edu/womens-health/fda-removes-menopause-hormone-therapy-black-box-warnings
CancerNetwork. "FDA Removes Black Box Warning for Breast Cancer and Other Indications on HRT Products." 2026. https://www.cancernetwork.com/view/fda-removes-black-box-warning-for-breast-cancer-and-other-indications-on-hrt-products
U.S. Food and Drug Administration. "FDA Approves Labeling Changes to Menopausal Hormone Therapy Products." FDA Press Announcements. https://www.fda.gov/news-events/press-announcements/fda-approves-labeling-changes-menopausal-hormone-therapy-products
Harvard Health Publishing. "FDA panel reviews menopause hormone therapy warnings." Harvard Medical School. https://www.health.harvard.edu/womens-health/fda-panel-reviews-menopause-hormone-therapy-warnings
"Menopausal Hormone Therapy—Risks, Benefits and Emerging Options: A Narrative Review." MDPI, Nov. 17, 2025. https://www.mdpi.com/1422-0067/26/22/11098
Espinoza D, Cruz NM, Lopez-Juarez N, et al. "Menopausal hormone therapy is associated with a 69% lower risk of low bone mineral density in postmenopausal women: a retrospective cohort study." Abstract ORF34-05, presented at ENDO 2026, Chicago, IL, June 13–16, 2026. https://www.endocrinologyadvisor.com/reports/menopausal-hormone-therapy-bone-mineral-density/
Blackburn I, Kunadian V. "Hormone replacement therapy and cardiovascular risk in postmenopausal women." European Heart Journal Open, 6(2), March 2026. https://doi.org/10.1093/ehjopen/oeag054
Age Management Medicine Group. "Hormone Replacement Therapy & Age Management Medicine: January 2026." https://agemed.org/e-journal/hormone-replacement-therapy-age-management-medicine-january-2026/
"Hormone Therapy for Menopause: Benefits, Risks & 2025 Research." Menopause Onset, June 2026. https://menopauseonset.com/hormone-therapy-deep-dive-understanding-benefits-risks-and-latest-research/
Buck ES, Lukas VA, Rubin RS. "Effective Prevention of Recurrent UTIs With Vaginal Estrogen: Pearls for a Urological Approach to Genitourinary Syndrome of Menopause." Urology. 2021 May;151:31-36. doi:10.1016/j.urology.2020.05.058. Epub 2020 Jun 10. PMID: 32533967. https://pubmed.ncbi.nlm.nih.gov/32533967/
